Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376897 | 0.98 | TSHR (0.36) | TSHRKDM4ERECQLHTR1BEPHX1 | |
| SCHEMBL27418647 | 0.91 | TSHR (0.35) | TSHRKDM4ERECQLHTR1BEPHX1 | |
| SCHEMBL15713284 | 0.90 | TSHR (0.43) | TSHRKDM4ERECQLHTR1BALDH1A1 | |
| SCHEMBL801169 | 0.87 | HTR1B (0.36) | TSHRKDM4ERECQLHTR1BHTR1D | |
| SCHEMBL13668379 | 0.87 | TSHR (0.40) | TSHRKDM4ERECQLHTR1BALDH1A1 | |
| SCHEMBL25828110 | 0.86 | TSHR (0.51) | TSHRKDM4ERECQLEPHX1ALDH1A1 | |
| SCHEMBL23651532 | 0.86 | KDM4E (0.42) | TSHRKDM4ERECQLHTR1BALDH1A1 | |
| SCHEMBL26765396 | 0.85 | TSHR (0.41) | TSHRKDM4ERECQLHTR1BALDH1A1 | |
| SCHEMBL31151042 | 0.83 | KDM4E (0.43) | TSHRKDM4ERECQLHTR1BALDH1A1 | |
| SCHEMBL22790666 | 0.83 | CYP2C19 (0.38) | TSHRKDM4ERECQLHTR1BHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | TSHR 3432/4885KDM4E 935/4885RECQL 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.